Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy
Open Access
- 1 November 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (11) , 6975-6982
Abstract
In invasive candidiasis, there has been an epidemiological shift from Candida albicans to non- albicans species infections, including infections with C. glabrata , C. parapsilosis , C. tropicalis , and C. krusei . Although the prevalence of C. krusei remains low among yeast infections, its intrinsic resistance to fluconazole raises epidemiological and therapeutic concerns. Echinocandins have in vitro activity against most Candida spp. and are the first-line agents in the treatment of candidemia. Although resistance to echinocandin drugs is still rare, individual cases of C. krusei resistance have been reported in recent years, especially with strains that have been under selective pressure. A total of 15 C. krusei strains, isolated from the blood, urine, and soft tissue of an acute lymphocytic leukemia patient, were analyzed. Strains developed echinocandin resistance during 10 days of caspofungin therapy. The molecular epidemiology of the isolates was investigated using two different typing methods: PCR-based amplification of the species-specific repetitive polymorphic CKRS-1 sequence and multilocus sequence typing. All isolates were genetically related, and the mechanism involved in decreased echinocandin susceptibility was characterized. Clinical resistance was associated with an increase in echinocandin MICs in vitro and was related to three different mutations in hot spot 1 of the target enzyme Fks1p. Molecular evidence of the rapid acquisition of resistance by different mutations in FKS1 highlights the need to monitor the development of resistance in C. krusei infections treated with echinocandin drugs.Keywords
This publication has 51 references indexed in Scilit:
- The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrataAntimicrobial Agents and Chemotherapy, 2012
- Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin BreakpointsAntimicrobial Agents and Chemotherapy, 2012
- Fungal echinocandin resistanceFungal Genetics and Biology, 2010
- Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility BreakpointAntimicrobial Agents and Chemotherapy, 2009
- Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008
- A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis , Candida orthopsilosis , and Candida metapsilosis Accounts for Reduced Echinocandin SusceptibilityAntimicrobial Agents and Chemotherapy, 2008
- Resistance to echinocandin-class antifungal drugsDrug Resistance Updates, 2007
- Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan SynthaseAntimicrobial Agents and Chemotherapy, 2007
- Effects of Caspofungin against Candida guilliermondii and Candida parapsilosisAntimicrobial Agents and Chemotherapy, 2006
- Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during TherapyAntimicrobial Agents and Chemotherapy, 2006